Guardian Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Guardian Partners’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,100	Closed	-$205K	–	203
2025 Q3	$205K	Sell	7,100 -7,700	-52%	-$195K	0.02%	177
2025 Q2	$386K	Sell	14,800 -20,000	-57%	-$438K	0.03%	148
2025 Q1	$758K	Buy	+34,800	New	+$874K	0.08%	113

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Guardian Partners's ARKG Position: Q4 2025 in Review

Guardian Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2025, closing a stake of 7,100 shares — an estimated $205K sold.

Guardian Partners first reported a position in ARKG in Q1 2025 and held it in 3 quarters. The position peaked at $758K in Q1 2025. 239 funds tracked by Wall St. Rank hold ARKG as of Q4 2025.

Guardian Partners reported no remaining ARK Genomic Revolution ETF position as of Q4 2025 after selling out during the quarter.
Guardian Partners sold 7,100 ARK Genomic Revolution ETF shares in Q4 2025, an estimated $205K.
Guardian Partners first reported a position in ARK Genomic Revolution ETF in Q1 2025 and held it in 3 quarters.
Guardian Partners's ARK Genomic Revolution ETF position peaked at $758K in Q1 2025.
239 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2025.

Based on Guardian Partners's 13F filing for Q4 2025, filed 17 Feb 2026.